Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 81 articles:
HTML format
Text format



Single Articles


    March 2017
  1. DI PASCOLI M, Ceranto E, De Nardi P, Donato D, et al
    Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.
    Dig Dis. 2017 Mar 1. doi: 10.1159/000458722.
    PubMed     Text format     Abstract available


    January 2017
  2. KEPPLER D
    Progress in the Molecular Characterization of Hepatobiliary Transporters.
    Dig Dis. 2017;35:197-202.
    PubMed     Text format     Abstract available


  3. HAUSSINGER D, Kordes C
    Mechanisms of Tauroursodeoxycholate-Mediated Hepatoprotection.
    Dig Dis. 2017;35:224-231.
    PubMed     Text format     Abstract available


  4. ALVAREZ-SOLA G, Uriarte I, Latasa MU, Urtasun R, et al
    Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
    Dig Dis. 2017;35:158-165.
    PubMed     Text format     Abstract available


    June 2016
  5. FITZ JG
    Hepatology after Hepatitis C.
    Dig Dis. 2016;34:603-606.
    PubMed     Text format     Abstract available


  6. DIAZ-GONZALEZ A, Reig M, Bruix J
    Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:597-602.
    PubMed     Text format     Abstract available


  7. HALILBASIC E, Fuchs C, Traussnigg S, Trauner M, et al
    Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Dig Dis. 2016;34:580-588.
    PubMed     Text format     Abstract available


    January 2016
  8. HOGDALL D, O'Rourke CJ, Taranta A, Oliveira DV, et al
    Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma.
    Dig Dis. 2016;34:440-51.
    PubMed     Text format     Abstract available


  9. SCHMIDT N, Thimme R
    Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:429-37.
    PubMed     Text format     Abstract available


  10. GERBES AL
    Liver Cirrhosis and Kidney.
    Dig Dis. 2016;34:387-90.
    PubMed     Text format     Abstract available


  11. GARCIA-TSAO G
    Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.
    Dig Dis. 2016;34:382-6.
    PubMed     Text format     Abstract available


  12. SAFFIOTI F, Pinzani M
    Development and Regression of Cirrhosis.
    Dig Dis. 2016;34:374-81.
    PubMed     Text format     Abstract available


  13. ZOLLER H, Henninger B
    Pathogenesis, Diagnosis and Treatment of Hemochromatosis.
    Dig Dis. 2016;34:364-73.
    PubMed     Text format     Abstract available


  14. JAHN D, Rau M, Wohlfahrt J, Hermanns HM, et al
    Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
    Dig Dis. 2016;34:356-63.
    PubMed     Text format     Abstract available


  15. THIMME R
    Highlights from Hepatology 2015: From Chronic Hepatitis to Hepatocellular Carcinoma.
    Dig Dis. 2016;34:I-II.
    PubMed     Text format    


  16. KUDO M
    Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors.
    Dig Dis. 2016;34:714-730.
    PubMed     Text format     Abstract available


  17. NISHIDA N, Kudo M
    Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations.
    Dig Dis. 2016;34:708-713.
    PubMed     Text format     Abstract available


  18. NAGAI T, Arao T, Nishio K, Matsumoto K, et al
    Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma.
    Dig Dis. 2016;34:702-707.
    PubMed     Text format     Abstract available


  19. OGAWA C, Minami Y, Morita M, Noda T, et al
    Prediction of Embolization Area after Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using SYNAPSE VINCENT.
    Dig Dis. 2016;34:696-701.
    PubMed     Text format     Abstract available


  20. KAWASAKI T, Hata KY, Kinoshita D, Takayama M, et al
    Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    Dig Dis. 2016;34:692-695.
    PubMed     Text format     Abstract available


  21. IWAMOTO T, Imai Y, Kogita S, Igura T, et al
    Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:679-686.
    PubMed     Text format     Abstract available


  22. ARIZUMI T, Ueshima K, Iwanishi M, Minami T, et al
    Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Dig Dis. 2016;34:671-678.
    PubMed     Text format     Abstract available


  23. CHISHINA H, Hagiwara S, Nishida N, Ueshima K, et al
    Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Dig Dis. 2016;34:659-664.
    PubMed     Text format     Abstract available


  24. YADA N, Sakurai T, Minami T, Arizumi T, et al
    Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.
    Dig Dis. 2016;34:650-653.
    PubMed     Text format     Abstract available


  25. SCORLETTI E, Byrne CD
    Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Dig Dis. 2016;34 Suppl 1:11-8.
    PubMed     Text format     Abstract available


  26. MAZZOTTI A, Caletti MT, Sasdelli AS, Brodosi L, et al
    Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction.
    Dig Dis. 2016;34 Suppl 1:3-10.
    PubMed     Text format     Abstract available


  27. MAHLI A, Hellerbrand C
    Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:32-9.
    PubMed     Text format     Abstract available


  28. SCHERER A, Dufour JF
    Treatment of Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:27-31.
    PubMed     Text format     Abstract available


  29. DE ALWIS NM, Anstee QM, Day CP
    How to Diagnose Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:19-26.
    PubMed     Text format     Abstract available


  30. MINAMI Y, Minami T, Chishina H, Kono M, et al
    US-US Fusion Imaging in Radiofrequency Ablation for Liver Metastases.
    Dig Dis. 2016;34:687-691.
    PubMed     Text format     Abstract available


  31. TAKITA M, Iwanishi M, Minami T, Kono M, et al
    Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease.
    Dig Dis. 2016;34:654-658.
    PubMed     Text format     Abstract available


  32. GALLE PR
    Extended Abstract: Management of Liver Cancer.
    Dig Dis. 2016;34:438-9.
    PubMed     Text format     Abstract available


  33. WEISKIRCHEN R, Tacke F
    Liver Fibrosis: From Pathogenesis to Novel Therapies.
    Dig Dis. 2016;34:410-22.
    PubMed     Text format     Abstract available


  34. LAMMERT F
    Genetics in Common Liver Diseases: From Pathophysiology to Precise Treatment.
    Dig Dis. 2016;34:391-5.
    PubMed     Text format     Abstract available


  35. CHAZOUILLERES O
    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Text format     Abstract available


  36. KOYAMA Y, Xu J, Liu X, Brenner DA, et al
    New Developments on the Treatment of Liver Fibrosis.
    Dig Dis. 2016;34:589-96.
    PubMed     Text format     Abstract available


    October 2015
  37. MINAMI Y, Murakami T, Kitano M, Sakurai T, et al
    Cone-Beam CT Angiography for Hepatocellular Carcinoma: Current Status.
    Dig Dis. 2015;33:759-764.
    PubMed     Text format     Abstract available


  38. NISHIDA N, Iwanishi M, Minami T, Chishina H, et al
    Hepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis Virus.
    Dig Dis. 2015;33:745-750.
    PubMed     Text format     Abstract available


  39. PISCAGLIA F, Iavarone M, Galassi M, Vavassori S, et al
    Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging.
    Dig Dis. 2015;33:735-744.
    PubMed     Text format     Abstract available


  40. ARIZUMI T, Ueshima K, Iwanishi M, Chishina H, et al
    Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
    Dig Dis. 2015;33:728-734.
    PubMed     Text format     Abstract available


  41. SUGIMOTO K, Kim SR, Imoto S, Tohyama M, et al
    Characteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging Detectability.
    Dig Dis. 2015;33:721-727.
    PubMed     Text format     Abstract available


  42. HASEGAWA Y, Kim SR, Hatae T, Ohta M, et al
    Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population.
    Dig Dis. 2015;33:715-720.
    PubMed     Text format     Abstract available


  43. KUDO M, Arizumi T, Ueshima K, Sakurai T, et al
    Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).
    Dig Dis. 2015;33:751-758.
    PubMed     Text format     Abstract available


  44. KUDO M, Kitano M, Sakurai T, Nishida N, et al
    Challenges of Clinical Research on Hepatocellular Carcinoma.
    Dig Dis. 2015;33:780-790.
    PubMed     Text format     Abstract available


  45. NISHIDA N, Kitano M, Sakurai T, Kudo M, et al
    Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
    Dig Dis. 2015;33:771-779.
    PubMed     Text format     Abstract available


    September 2015
  46. KAWAGUCHI Y, Hasegawa K, Tanaka N, Ishizawa T, et al
    Advances in Assessment and Planning for Surgical Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2015;33:683-690.
    PubMed     Text format     Abstract available


  47. BADREALAM KF, Owais M
    Nano-Sized Drug Delivery Systems: Development and Implication in Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2015;33:675-682.
    PubMed     Text format     Abstract available


  48. CABIBBO G, Petta S, Maida M, Camma C, et al
    Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.
    Dig Dis. 2015;33:668-674.
    PubMed     Text format     Abstract available


  49. SACCO R, Giorgi L, Fornaro L, Bargellini I, et al
    Trans-Arterial Radioembolization for Hepatocellular Carcinoma.
    Dig Dis. 2015;33:661-667.
    PubMed     Text format     Abstract available


  50. YAMASHITA YI, Shirabe K, Aishima S, Maehara Y, et al
    Predictors of Microvascular Invasion in Hepatocellular Carcinoma.
    Dig Dis. 2015;33:655-660.
    PubMed     Text format     Abstract available


  51. SASAKI M, Nakanuma Y
    Serum Amyloid A-Positive Hepatocellular Neoplasm: A New Type of Tumor Arising in Patients with Advanced Alcoholic Disease.
    Dig Dis. 2015;33:648-654.
    PubMed     Text format     Abstract available


  52. YOPP AC, Choti MA
    Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Dig Dis. 2015;33:642-647.
    PubMed     Text format     Abstract available


  53. CRITELLI RM, De Maria N, Villa E
    Biology of Hepatocellular Carcinoma.
    Dig Dis. 2015;33:635-641.
    PubMed     Text format     Abstract available


    January 2015
  54. HARA E
    Relationship between Obesity, Gut Microbiome and Hepatocellular Carcinoma Development.
    Dig Dis. 2015;33:346-50.
    PubMed     Text format     Abstract available


  55. RIDLON JM, Kang DJ, Hylemon PB, Bajaj JS, et al
    Gut microbiota, cirrhosis, and alcohol regulate bile Acid metabolism in the gut.
    Dig Dis. 2015;33:338-45.
    PubMed     Text format     Abstract available


  56. NAIK J, de Waart DR, Utsunomiya K, Duijst S, et al
    ATP8B1 and ATP11C: Two Lipid Flippases Important for Hepatocyte Function.
    Dig Dis. 2015;33:314-8.
    PubMed     Text format     Abstract available


  57. BAILLY F, Pradat P, Virlogeux V, Zoulim F, et al
    Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Dig Dis. 2015;33:613-23.
    PubMed     Text format     Abstract available


  58. BOETTLER T, Thimme R
    Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
    Dig Dis. 2015;33:608-12.
    PubMed     Text format     Abstract available


  59. TRAUSSNIGG S, Kienbacher C, Halilbasic E, Rechling C, et al
    Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Dig Dis. 2015;33:598-607.
    PubMed     Text format     Abstract available


  60. STEIB CJ, Schewe J, Gerbes AL
    Infection as a Trigger for Portal Hypertension.
    Dig Dis. 2015;33:570-6.
    PubMed     Text format     Abstract available


  61. DIREKZE S, Jalan R
    Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy.
    Dig Dis. 2015;33:562-9.
    PubMed     Text format     Abstract available


  62. WEISSENBORN K
    The Clinical Relevance of Minimal Hepatic Encephalopathy - A Critical Look.
    Dig Dis. 2015;33:555-61.
    PubMed     Text format     Abstract available


  63. CAVALLIN M, Fasolato S, Marenco S, Piano S, et al
    The Treatment of Hepatorenal Syndrome.
    Dig Dis. 2015;33:548-54.
    PubMed     Text format     Abstract available


  64. WONG F
    Definition and Diagnosis of Acute Kidney Injury in Cirrhosis.
    Dig Dis. 2015;33:539-47.
    PubMed     Text format     Abstract available


  65. SOLA E, Gines P
    Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis.
    Dig Dis. 2015;33:534-8.
    PubMed     Text format     Abstract available


  66. ABRALDES JG, Tandon P
    Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt - When and How?
    Dig Dis. 2015;33:524-33.
    PubMed     Text format     Abstract available


  67. FRIEDMAN SL
    Hepatic Fibrosis: Emerging Therapies.
    Dig Dis. 2015;33:504-7.
    PubMed     Text format     Abstract available


  68. JAESCHKE H
    Acetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients.
    Dig Dis. 2015;33:464-71.
    PubMed     Text format     Abstract available


  69. PARES A
    Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Dig Dis. 2015;33 Suppl 2:125-33.
    PubMed     Text format     Abstract available


  70. HERKEL J
    Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases.
    Dig Dis. 2015;33 Suppl 2:70-4.
    PubMed     Text format     Abstract available


  71. JOPSON L, Jones DE
    Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management.
    Dig Dis. 2015;33 Suppl 2:109-14.
    PubMed     Text format     Abstract available


  72. CORRIGAN M, Hirschfield GM
    Aspects of the Pathophysiology of Primary Biliary Cirrhosis.
    Dig Dis. 2015;33 Suppl 2:102-8.
    PubMed     Text format     Abstract available


  73. KOHLI R, Myronovych A, Tan BK, Salazar-Gonzalez RM, et al
    Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
    Dig Dis. 2015;33:440-6.
    PubMed     Text format     Abstract available


  74. TRAUNER M, Halilbasic E, Claudel T, Steinacher D, et al
    Potential of nor -Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
    Dig Dis. 2015;33:433-9.
    PubMed     Text format     Abstract available


  75. SANYAL AJ
    Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Dig Dis. 2015;33:426-32.
    PubMed     Text format     Abstract available


  76. MASYUK TV, Masyuk AI, LaRusso NF
    TGR5 in the Cholangiociliopathies.
    Dig Dis. 2015;33:420-5.
    PubMed     Text format     Abstract available


  77. ZIMMER V, Liebe R, Lammert F
    Nuclear receptor variants in liver disease.
    Dig Dis. 2015;33:415-9.
    PubMed     Text format     Abstract available


  78. KRONES E, Wagner M, Eller K, Rosenkranz AR, et al
    Bile Acid-induced cholemic nephropathy.
    Dig Dis. 2015;33:367-75.
    PubMed     Text format     Abstract available


  79. ABU-HAYYEH S, Williamson C
    Progesterone metabolites as farnesoid X receptor inhibitors.
    Dig Dis. 2015;33:300-6.
    PubMed     Text format     Abstract available


  80. VAN BUUREN HR, Lammers WJ, Harms MH, Hansen BE, et al
    Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:118-24.
    PubMed     Text format     Abstract available


  81. POUPON R
    Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:115-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: